Literature DB >> 33066718

IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus.

Eric G Meissner1, Dongjun Chung2,3, Betty Tsao4, David W Haas5,6, Netanya S Utay7.   

Abstract

Immune non-responders (INRs) are people with HIV infection who fail to restore their CD4 T-cell counts in spite of prolonged virologic suppression, a condition associated with higher rates of all-cause mortality. The mechanisms of immune non-response are not entirely clear. We used existing clinical and genetic data from AIDS Clinical Trials Group clinical trials to ask whether an IFNL4 single-nucleotide polymorphism, shown to be associated with outcomes for other infectious diseases, correlated with immune non-response for HIV. Analysis of data from 426 participants with clearly defined CD4 T-cell recovery phenotypes, including 88 INRs with CD4 < 200 cells/mm3 after 2 years of suppressive antiretroviral therapy, did not identify an association of IFNL4 genotype with immune non-response. Thus, the IFNL4 genotype is unlikely to influence immunologic recovery.

Entities:  

Keywords:  CD4 T-cell recovery; HIV; IFNL4 genotype; immune non-response

Mesh:

Substances:

Year:  2020        PMID: 33066718      PMCID: PMC8020497          DOI: 10.1089/AID.2020.0104

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  45 in total

1.  Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART.

Authors:  Giulia Marchetti; Lidia Gazzola; Daria Trabattoni; Francesca Bai; Giuseppe Ancona; Laurenzia Ferraris; Luca Meroni; Massimo Galli; Mario Clerici; Andrea Gori; Antonella D'Arminio Monforte
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.

Authors:  Colleen F Kelley; Christina M R Kitchen; Peter W Hunt; Benigno Rodriguez; Frederick M Hecht; Mari Kitahata; Heide M Crane; James Willig; Michael Mugavero; Michael Saag; Jeffrey N Martin; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

Review 3.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.

Authors:  Lidia Gazzola; Camilla Tincati; Giusi Maria Bellistrì; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

4.  Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

Authors:  Thomas R O'Brien; Ruth M Pfeiffer; Ashley Paquin; Krystle A Lang Kuhs; Sabrina Chen; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Gregory D Kirk; Mark H Kuniholm; Timothy R Morgan; Howard D Strickler; David L Thomas; Ludmila Prokunina-Olsson
Journal:  J Hepatol       Date:  2015-07-15       Impact factor: 25.083

5.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

6.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

7.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Authors:  Maura Manion; Benigno Rodriguez; Kathleen Medvik; Gareth Hardy; Clifford V Harding; Robert T Schooley; Richard Pollard; David Asmuth; Robert Murphy; Edward Barker; Kirsten E Brady; Alan Landay; Nick Funderburg; Scott F Sieg; Michael M Lederman
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  1 in total

1.  IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men.

Authors:  Giovanna Meza; Fátima Galián; Claudia Jaimes-Bernal; Francisco J Márquez; Faruk Sinangil; Carolina Scagnolari; Luis Miguel Real; Donald Forthal; Antonio Caruz
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.